Influence of Interferon-α on Cytokine Expression by the Bone Marrow Microenvironment—Impact on Treatment of Myeloproliferative Disorders

References

• Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y., Daley G. Q., Mes-Masson A. M., Witte O. N., Baltimore D. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science 1986; 233: 212
   PubMed Web of Science ®Google Scholar
• de Klein A., van Kessel A. G., Grosfeld G., Bartram C. R., Hagemeijer A., Bootsma D., Spurr N. K., Heisterkamp N., Groffen J., Stephenson J. R. A cellular oncogene (c-abl) is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 1982; 294: 765
   Google Scholar
• Konopka J. B., Watanabe S. M., Witte O. N. An alteration of the human c-abl protein in K562 cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035
   PubMed Web of Science ®Google Scholar
• McWhirter J. R., Wang J. Y. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of philadelphia chromosome-positive human leukemias. EMBO J. 1991; 12: 1533
   Web of Science ®Google Scholar
• Sirard C., Laneuville P., Dick J. E. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83: 1575
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Baltimore D. Tranformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 9312
   PubMed Web of Science ®Google Scholar
• Elefanty A. G., Hariharan I. K., Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990; 9: 1069
   PubMed Web of Science ®Google Scholar
• Kelliher M. A., McLaughlin J., Witte O. N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. U.S.A. 1990; 87: 6649
   PubMed Web of Science ®Google Scholar
• Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P. K., Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344: 251
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Th'ng K. H., Lowenthal R. M. In vitro colony forming cells and colony stimulating factor in chronic granulocytic leukemia. Br. J. Cancer 1974; 30: 1
   PubMed Web of Science ®Google Scholar
• Lepine J., Messner H. A. Pluripotent hemopoietic progenitors (CFU-GEMM) in chronic myelogenous leukemia. Int. J. Cell Cloning 1983; 1: 230
   PubMedGoogle Scholar
• Emanuel P. D., Bates L. J., Castleberry R. P., Gualtieri R. J., Zuckerman K. S. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77: 925
   PubMed Web of Science ®Google Scholar
• Bedi A., Zehnbauer B. A., Barber J. P., Sharkis S. J., Jones R. J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038
   PubMed Web of Science ®Google Scholar
• McGahon A., Bissonnette R., Schmitt M., Cotter K. M., Green D. R., Cotter T. G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179
   PubMed Web of Science ®Google Scholar
• Bedi A., Barber J. P., Bedi G. C., El-Deiry W. S., Sidransky D., Vala M. S., Akhtar A. J., Hilton J., Jones R. J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148
   PubMed Web of Science ®Google Scholar
• Schwab R., Peschel C., Derigs G., Fischer T., Huber C., Aulitzky W. E. Deficient cell cycle control upon gamma irradiation and growth factor starvation in immature myeloid cells from chronic phase CML patients Cytokines and Molecular Therapy. 1995
   Google Scholar
• Eaves A. C., Cashman J. D., Gaboury L. A., Kalousek D. K., Eaves C. J. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 5306
   PubMed Web of Science ®Google Scholar
• Cashman J. D., Eaves A. C., Eaves C. J. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism. Blood 1994; 84: 1534
   PubMed Web of Science ®Google Scholar
• Gordon M. Y., Dowding C. R., Riley G. P., Goldman J. M., Greaves M. F. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukemia. Nature 1987; 328: 342
   PubMed Web of Science ®Google Scholar
• Gordon M. Y., Atkinson J., Clarke D., Dowding C. R., Goldman J. M., Grimsley P. G., Siczkowski M., Greaves M. F. Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia. Leukemia 1991; 5: 693
   PubMed Web of Science ®Google Scholar
• Verfaille C. M., McCarthy J. B., McGlave P. B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J. Clin. Invest. 1992; 90: 1992
   PubMed Web of Science ®Google Scholar
• Eaves C. J., Cashman J. D., Wolpe S. D., Eaves A. C. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein I alpha, an inhibitor of primitive normal hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 12015
   PubMed Web of Science ®Google Scholar
• Estrov Z., Kurzrock R., Wetzler M., Kantarjian H., BlakeHarris M., Gutterman J. U., Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity. Blood 1991; 78: 1476
   PubMed Web of Science ®Google Scholar
• Wetzler M., Kurzrock R., Lowe D. G., Kantarjian H., Gutterman J. U., Talpaz M. Alteration in bone marrow adherent layer growth factor expression: No novel mechanism of chronic myelogenous leukemia progression. Blood 1991; 78: 2400
   PubMed Web of Science ®Google Scholar
• Klein H., Becher R., Lübbert M., Oster W., Schleiermacher E., Brach M. A., Souza L., Lindemann A., Mertelsmann R., Herrmann F. Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia progression. J. Exp. Med. 1990; 171: 1785
   PubMed Web of Science ®Google Scholar
• Herrmann F., Helfrich S. G., Lindemann A., Schleiermacher E., Huber C., Mertelsmann R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alpha-2b in chronic myelogenous leukemia. J. Clin. Oncol. 1992; 10: 631
   PubMed Web of Science ®Google Scholar
• Casadevall B., Vainchenker W., Lacombe C. Erythroid progenitors in polycythemia vera: Demonstration of their hypersensitivity to erythropoietin using serum free cultures. Blood 1982; 59: 447
   PubMed Web of Science ®Google Scholar
• Zanjani E. D., Lutton J. D., Hoffman R., Wasserman L. R. Erythroid colony formation by polycythemia vera bone marrow in vitro: Dependence on erythropoietin. J. Clin. Invest. 1977; 59: 841
   PubMed Web of Science ®Google Scholar
• Fisher M. J., Prchal J. F., Prchal J. T., D'Andrea A. D. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84: 1982
   PubMed Web of Science ®Google Scholar
• de Wolf J. T., Hendriks D. W., Esselink M. T., Halie M. R., Vellenga E. The effects of IL-1 and IL-4 on the Epo-independent erythroid progenitor in polycythemia vera. Br. J. Haematol. 1994; 88: 12
   Google Scholar
• Dai C. H., Krantz S. B., Dessypris E. N., Means R. T., Horn S. T., Gilbert H. S. Polycythemia vera II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony stimulating factor. Blood 1992; 80: 891
   PubMed Web of Science ®Google Scholar
• de Wolf J. T., Beentjes J. A., Esselink M. T. In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin. Exp. Hematol. 1989; 17: 981
   PubMed Web of Science ®Google Scholar
• Dai C. H., Krantz S. B., Green W. F., Gilbert H. S. Polycythemia vera III. Burst forming units erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br. J. Haematol. 1994; 86: 12
   PubMed Web of Science ®Google Scholar
• Muller E. W., de Wolf J. T., Hendriks D. W., Esselink M. T., Halie M. R., Vellenga E. Recombinant human mast cell growth factor supports erythroid colony formation in polycythemia vera in the presence and absence of erythropoietin and serum. Exp. Hematol. 1995; 21: 1353
   Web of Science ®Google Scholar
• Correa P. N., Eskinazi D., Axelrad A. A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: Studies in an improved serum-free medium. Blood 1994; 83: 99
   PubMed Web of Science ®Google Scholar
• Mirza A. M., Correa P. N., Axelrad A. A. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor-1 receptor β subunit in circulating mononuclear cells of patients with polycythemia vera. Blood, 86: 877
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H. Current aspects of drug therapy in Philadelphia-positive CML: Correlation of tumor burden with survival. Leuk. Lymphoma. 1995
   Web of Science ®Google Scholar
• Reilly J. T., Vellenga E., de Wolff J. T. M. Interferon treatment in polycythemia vera. Leuk. Lymphoma. 1995
   PubMed Web of Science ®Google Scholar
• Lengfelder E., Griesshammer M., Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk. Lymphoma. 1995
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: A concise update. Blood 1993; 82: 691
   PubMed Web of Science ®Google Scholar
• Aulitzky W. E., Peschel C., Schneller F., Huber C. Biotherapy of chronic myelogenous leukemia. Ann. Hematol., 70: 113
   PubMed Web of Science ®Google Scholar
• Allan N. C., Shepherd P. C. A., Richards S. M. UK Medical Research Council randomised multicentre trial of interferon alpha n1 for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment od chronic myeloid leukemia. N. Engl. J. Med. 1994; 330: 820
   PubMed Web of Science ®Google Scholar
• Messora C., Bensi L., Vecchi A., Longo R., Giacobbi F., Temperani P., Bevini M., Emilia G., Sacchi S. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Brit. J. Haematol. 1994; 86: 402
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. E., Lu L., Platzer E., Felt C., Juliano L., Rubin B. Y. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-e) and granulocyte-macrophage (CFU-GM) progenitor cells. J. Immunol. 1983; 131: 1300
   PubMed Web of Science ®Google Scholar
• Raefsky E. L., Platanias L. C., Zoumbos N. C., Young N. S. Studies of interferon as a regulator of hematopoietic cell proliferation. J. Immunol. 1985; 135: 2507
   PubMed Web of Science ®Google Scholar
• Ganser A., Carlo-Stella C., Greher J., Völkers B., Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987; 70: 1173
   PubMed Web of Science ®Google Scholar
• Geissler D., Gastl G., Aulitzky W. E., Tilg H., Gaggl S., Kon-Walinka G., Huber C. Recombinant interferon alpha-2c in chronic myelogenous leukemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro. Leuk. Res. 1990; 14: 629
   PubMed Web of Science ®Google Scholar
• Dowding C., Guo A. P., Maisin D., Gordon M. Y., Goldman J. M. The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. Brit. J. Haematol. 1991; 77: 165
   PubMed Web of Science ®Google Scholar
• Mazur E. M., Richtsmeier W. J., South K. Alpha-interferon: differential suppression of colony growth from human erythroid, myeloid, and megakaryocytic hemopoietic progenitor cells. J. Interferon. Res. 1986; 6: 199
   PubMedGoogle Scholar
• Galvani D. W., Cawley J. C. Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Brit. J. Haematol. 1989; 73: 475
   PubMed Web of Science ®Google Scholar
• Després D, Goldschmitt J, Aulitzky W. E., Huber C., Peschel C. Differential effect of type 1 interferons on hematopoietic progenitor cells: Failure of IFNs to inhibit immature myeloid progenitor cells from normal bone marrow and chronic myelogeneous leukemia. [In Press. Exp. Hematol. 1995
   PubMed Web of Science ®Google Scholar
• Lotem J., Sachs L. Selective regulation of the activity of different hematopoietic regulatory proteins by transforming growth factor beta 1 in normal and leukemic myeloid cells. Blood 1990; 76: 1315
   PubMed Web of Science ®Google Scholar
• Moore S. C., Theus S. A., Barnett J. B., Soderberg L. S. Bone marrow natural suppressor cells inhibits the growth of myeloid progenitor cells and the synthesis of colony-stimulating factors. Exp. Hematol. 1992; 20: 1178
   PubMed Web of Science ®Google Scholar
• Keller J. R., Bartelmez S. H., Sitnicka E., Ruscetti F. W., Ortiz M., Gooya J. M., Jacobsen S. E. Distinct and overlapping direct effects of macrophage inflammatory protein-1 alpha and transforming growth factor beta on hematopoietic progenitor/stem cell growth. Blood 1994; 84: 2175
   PubMed Web of Science ®Google Scholar
• Dowding C., Guo A. P., Osterholz J., Siczkowski M., Goldman J. M., Gordon M. Y. Interferon-alpha overrides the deficient adhesion of chronic myeloid primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78: 499
   PubMed Web of Science ®Google Scholar
• Upadhyaya G., Cuba S. C., Sih S. A., Feinberg A. P., Talpaz M., Kantarjian H. M., Deisseroth A. B., Emerson S. G. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J. Clin. Invest. 1991; 88: 2131
   PubMed Web of Science ®Google Scholar
• Bhatia R., Wayner E. A., McGlave P. B., Verfaillie C. M. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function [see comments]. J. Clin. Invest. 1994; 94: 384
   PubMed Web of Science ®Google Scholar
• Santucci M. A., Soligo D., Piled S., Zuffa E., Testoni N., Tura S. Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leuk. Lymphoma, 11(Suppl 1)113
   PubMedGoogle Scholar
• Beelen D. W., Graeven U., Elmaagacli A. H., Niederle N., Kloke O., Opalka B., Schaefer U. W. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981
   PubMed Web of Science ®Google Scholar
• Aman M. J., Keller U., Derigs G., Mohamadzadeh M., Huber C., Peschel C. Regulation of cytokine expression by interferon alpha in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of IL-1 receptor antagonist. Blood 1994; 83: 4142
   Google Scholar
• Aman M. J., Rudolf G., Goldschmitt J., Aulitzky W. E., Lam C., Huber C., Peschel C. Type I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 1993; 82: 2371
   PubMed Web of Science ®Google Scholar
• Aman M. J., Bug G., Huber C., Peschel C. Inhibition of interleukin-11 by interferon-alpha in human bone marrow stromal cells. 1995
   Google Scholar
• Schindler R., Ghezzi P., Dinarello C. A. IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccaride-induced transcription of IL-1. J. Immunol. 1990; 144: 2216
   PubMed Web of Science ®Google Scholar
• Bartelmez S. H., Stanley R. E. Synergism between hemopoietic growth factors (HGFs) detected by their effects on cells bearing receptors for a lineag specific HGF: Assay for hemopoietin-1. J. Cell. Physiol. 1985; 122: 370
   PubMed Web of Science ®Google Scholar
• Mochizuki D. Y., Eisenman J. F., Conlon P. J., Larsen A. D., Tushinski R. J. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 5267
   PubMed Web of Science ®Google Scholar
• Yang Y.-C., Tsai S., Wong G. G., Clark S. C. Interleukin-1 regulation of hematopoietic growth factor production by human stromal fibroblasts. J. Cell. Physiol. 1988; 134: 292
   PubMed Web of Science ®Google Scholar
• Fibbe W. E., Gosenlink H. M., Van Eeden G., Van Damme J., Biliau A., Voogt P. J., Willemze R., Falkenburg J. H. F. Proliferation of myelopid progenitor cells in human longterm bone marrow cultures is stimulated by interleukin-1 beta. Blood 1988; 72: 1242
   PubMed Web of Science ®Google Scholar
• Van Damme J., Opdenakker G., Simpson R. J., Rubira M. R., Cayphas S., Vink A., Biliau A., Van Snick J. Identification of the human 26 kD protein, interferon β2 (IFN-β2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosi. factor. J. Exp. Med. 1987; 165: 914
   PubMed Web of Science ®Google Scholar
• Elias J. A., Zheng T., Whiting N. L., Trow T. K., Merrill W. W., Zitnik R., Ray P., Alderman E. M. IL-1 and transforming growth factor-beta regulation of fibroblast-derived IL-11. J. Immunol. 1994; 152: 2421
   PubMed Web of Science ®Google Scholar
• Yang L., Yang Y. C. Regulation of interleukin (IL)-11 gene expression in IL-1 induced primate bone marrow stromal cells. J. Biol. Chem. 1994; 269: 32732
   PubMed Web of Science ®Google Scholar
• Aye M. T., Hashemi S., Leclair B., Zeibdawi A., Trudel E., Halpenny M., Fuller V., Cheng G. Expression of stem cell factor and c-kit mRNA in cultured endothelial cells, monocytes and cloned human bone marrow cells (CFU-RF). Exp. Hematol. 1992; 20: 523
   PubMed Web of Science ®Google Scholar
• Koenig A., Yakisan E., Reuter M., Huang M., Sykora K. W., Corbacioglu S., Welte K. Differential regulation of stem cell factor mRNA expression in human endothelial cells by bacterial pathogens: an in vitro model of inflammation. Blood 1994; 83: 2836
   PubMed Web of Science ®Google Scholar
• Tilg H., Mier J. W., Vogel W., Aulitzky W. E., Wiedemann C. J., Vannier E., Huber C., Dinarello C. A. Induction of circulating IL-1 receptor antagonist by IFN treatment. J. Immunol. 1993; 150: 4687
   PubMed Web of Science ®Google Scholar
• Peschel C., Bug G., Aman M. J., Huber C. Tissue specific regulation of the expression of macrophage inflammatory protein 1α (MIP-1α). [Abstract. Exp. Hematol. 1995; 23: 93
   Google Scholar
• Wadenvik H., Kutti J., Ridell B., Revesz P., Jacobsson S., Magnusson B., Westin J., Vilen L. The effect of α-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 1991; 77: 2103
   PubMed Web of Science ®Google Scholar